Inovio Pharmaceuticals, Inc. (NASDAQ: INO) Chief Financial Officer Peter Kies sold 10,000 shares of the company in a trade that took place on Thursday, June 3. The shares were sold at an average price of $ 8.03 for a total value of $ 80,300.00. As a result of the transaction, the CFO now directly owns 150,788 shares of the company, valued at $ 1,210,827.64. The transaction was disclosed in a file with the Securities & Exchange Commission, which is available at this hyperlink.
Peter Kies also recently completed the following transactions:
- On Wednesday April 21, Peter Kies sold 10,000 shares of Inovio Pharmaceuticals. The stock was sold for an average price of $ 8.52, for a total value of $ 85,200.00.
NASDAQ INO traded up $ 0.05 on Friday, reaching $ 7.94. The company’s shares had a trading volume of 3,113,609 shares, compared to its average volume of 12,386,988. Inovio Pharmaceuticals, Inc. has a twelve-month low of $ 5.81 and a twelve-month high of $ 33.79. The company has a current ratio of 14.17, a rapid ratio of 14.17 and a debt ratio of 0.02. The company has a 50-day moving average price of $ 7.77. The company has a market cap of $ 1.66 billion, a PE ratio of -6.98 and a beta of 0.67.
Inovio Pharmaceuticals (NASDAQ: INO) last released its quarterly results on Monday, May 10. The biopharmaceutical company reported ($ 0.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters consensus estimate of ($ 0.18) of ($ 0.09). Inovio Pharmaceuticals recorded a negative return on equity of 39.16% and a negative net margin of 2,916.64%. The company posted revenue of $ 0.40 million in the quarter, compared to analysts’ estimates of $ 1.06 million. The company’s revenue for the quarter was down 69.2% from the same quarter last year. As a group, sell-side analysts expect Inovio Pharmaceuticals, Inc. to post EPS of -1.07 for the current fiscal year.
INO has been the subject of several recent research reports. Oppenheimer reiterated a “buy” note on Inovio Pharmaceuticals shares in a research note on Friday, April 16. Piper Sandler lowered its target price on Inovio Pharmaceuticals shares from $ 7.00 to $ 6.00 and established a “neutral” rating for the company in a research report released on Monday, May 10. Zacks investment research downgraded Inovio Pharmaceuticals from a “keep” rating to a “sell” rating in a research report released Thursday, May 13. Bank of America began covering Inovio Pharmaceuticals in a research report on Tuesday, March 23. They issued a “neutral” rating and a target price of $ 13.00 on the stock. Finally, HC Wainwright reissued a “hold” note on Inovio Pharmaceuticals shares in a research note on Friday April 16. Two investment analysts gave the stock a sell rating, five issued a conservation rating and three gave the company a buy rating. Inovio Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $ 15.78.
Several hedge funds and other institutional investors recently changed their positions in INO. Charles Schwab Investment Management Inc. increased its stake in Inovio Pharmaceuticals by 1.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,095,477 shares of the biopharmaceutical company valued at $ 9,695,000 after purchasing an additional 19,369 shares during the period. Greenwich Wealth Management LLC purchased a new equity stake in Inovio Pharmaceuticals in the 4th quarter for a value of approximately $ 107,000. Pacer Advisors Inc. increased its position in Inovio Pharmaceuticals shares by 48.2% in the fourth quarter. Pacer Advisors Inc. now owns 11,967 shares of the biopharmaceutical company valued at $ 106,000 after purchasing an additional 3,894 shares during the period. Virtus ETF Advisers LLC purchased a new position in Inovio Pharmaceuticals shares during the fourth quarter valued at $ 251,000. Finally, Keystone Financial Group strengthened its position in Inovio Pharmaceuticals by 20.3% in the 4th quarter. Keystone Financial Group now owns 39,075 shares of the biopharmaceutical company valued at $ 346,000 after acquiring an additional 6,600 shares during the period. 35.18% of the shares are held by institutional investors and hedge funds.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc, a biotechnology company, is focused on the discovery, development and commercialization of DNA-based drugs to treat and protect people against diseases associated with human papillomavirus (HPV), cancer and infectious diseases. Its DNA-based drug platform uses precisely engineered SynCon optimized plasmids that have the ability to help break the immune system’s tolerance to cancerous or infected cells and to facilitate protection against cross-strains against variants. of unmatched and matched pathogens.
Featured Article: Why is Cost of Goods Sold Important?
This instant news alert was powered by storytelling technology and MarketBeat financial data to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured article: Systematic risk and investors
7 cryptocurrencies that lead the market higher
Capital influx drives cryptocurrency up
There is an influx of money into the cryptocurrency market that is pushing the whole complex higher. Not only is institutional interest peaking, but recognition and use is also increasing. With Bitcoin setting new all-time highs 100% above the highs of 2017, the number of new Bitcoin millionaires is also on the rise.
But Bitcoin isn’t by far the only cryptocurrency on the market today. The number of cryptocurrencies on the market has grown steadily with over 4,000 listed on Coinmarketcap alone. But that doesn’t mean they’re all worth your time. Many, if not most, will not stand the test of time.
One way to judge the market’s interest in a cryptocurrency is its performance gains in the market. A cryptocurrency that is growing in value is definitely the one you might want to own. The best method for judging the market’s interest in a cryptocurrency is market capitalization. The cryptocurrency market is worth over $ 1,000 billion and growing, and most of that value centers around the top seven. Together, the 3,993 lowest cryptocurrencies represent only 12% of the market and have yet to prove lasting value.
See the “7 Cryptocurrencies That Lead the Market Higher”.